APAC Hemophilia A and B Markets to See Rapid Growth to 2022, Projects GBI Research in Its Report Available at MarketPublishers.com09 Dec 2016 • by Natalie Aster
LONDON – The hemophilia A and B markets in the APAC region are poised to register CAGRs of 6.7% and 5.8% to reach values of USD 699.1 million and USD 112.9 million, respectively, by end-2022.
The pipeline encompasses a set of molecular targets and molecule types, comprising those well entrenched in the hemophilia A and B marketplace, and also novel targeted treatment modalities.
The present-day landscape of the marketed products comprises replacement factor treatments, like recombinant therapies and novel long-acting recombinant drug products.
Co-development deals are the typical strategic alliance type in the hemophilia A and B universe, with overall deal values standing from around USD 10 million to over USD 280 million.
Although late-stage pipeline to treat hemophilia appear to exhibit strong promise, the major restraint to the market growth is expected to be low penetration levels of novel long-acting recombinant factor VIII therapies across China and India, on the back of their high projected prices.
Topical market research report “Hemophilia A and B Therapeutics in Asia-Pacific Markets to 2022” prepared by GBI Research offers a detailed guide to the market on a regional level focusing on China, India, Japan, Australia and South Korea. The study contains a detailed review of the disease’s pathogenesis, diagnosis, prognosis, therapies available, etc. It identifies key therapies for each subset of patients, alongside their commercial and clinical status; highlights unmet needs. The research publication sheds light on the hemophilia A and B pipeline, categorising pipeline therapies based on development stage, molecular type and target. It throws light on the potential of late-stage hemophilia A and B therapies, with comprehensive profiles of products that will likely come to the market in the forthcoming years, casting light on the clinical performance, commercial standing, and prospective competitiveness. Furthermore, it gives detailed forecasts of the market growth in the region’s 5 leading markets with epidemiology forecasts and annual treatment cost projections, and also individual contributions of high-potential late-stage molecules to the sector’s growth. A shrewd look at the major trends in co-development and licensing deals is also given in the report.
More in-demand reports by our partner are available at GBI Research page.